InsidersTradesSigma
Follow the HLB stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, HLB has recorded 54 reports. Market capitalisation: €5,620.6bn. The latest transaction was reported on 9 June 2026 (Purchase). Among the most active insiders: 진양곤. The full history is free.
52
Insider Decl.
n/a
Thresholds
n/a
28 ops.
Buy Volume
n/a
2 ops.
Sell Volume
Fundamental score
Ranked 24,723 of 29,024 companies
26.6
score / 100
Value26
Quality27
FCF yld-2.3%
Earn yld-4.6%
EV/EBITDA·
ROE-48%
Gross mgn33%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 June 2026
Declarations54 total
Other
Other
1,391,297 sharesKRXDART:20260609000183
44,728 sharesKRXDART:20260303001765
25 of 54 declarations
About HLB
HLB is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative treatments and therapeutic solutions.